The intravenous immunoglobulin market was valued at USD 12.66 billion in 2023 and is expected to reach USD 13.57 billion in 2024 and USD 24.13 billion by 2032, expanding at a CAGR of 7.50% during the forecast period 2024–2032. Demand reflects the increasing prevalence of immune-mediated disorders, advances in plasma collection and fractionation, and wider awareness of IVIG therapy. This analysis examines application breadth, distribution dynamics, and recent regulatory milestones relevant to B2B stakeholders.

Immune-Mediated Disorders and the Therapeutic Mechanism

IVIG works by introducing antibodies from healthy individuals into the bloodstream of patients, providing passive immunity. These antibodies can neutralize pathogens, enhance immune responses, and reduce the severity or duration of infection. The therapy is a viable option for specific infectious diseases that significantly affect the immune system. Market expansion is expected to continue with rising healthcare expenditure, a growing geriatric population, and the expanding off-label use of IVIG. The ecosystem spans pharmaceutical companies, plasma collection centers, contract manufacturing organizations, distributors, hospitals, clinics, and patients, and is influenced by regulatory policies, reimbursement systems, and regional dynamics.

Application Breadth: From CIDP to Immune Thrombocytopenia

The report segments applications into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, and Guillain-Barre syndrome. Immunodeficiency diseases held the largest share in 2022.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/global-intravenous-immunoglobulin-market

IVIG is used to alleviate symptoms of certain inflammatory immune conditions and to boost immunoglobulin levels when they are low or have decreased because of other medications such as rituximab. In March 2024, Argenx SE announced that Japan's Ministry of Health, Labour, and Welfare approved VYVGART (efgartigimod alfa) for intravenous use in adults with primary immune thrombocytopenia, expanding treatment options for this autoimmune disorder. Immunodeficiency diseases themselves are either primary (usually genetic and present from birth) or secondary (developing later in life through infections, medications, or medical treatments).

Retail Pharmacies Gain Importance in Distribution

The distribution channel segment comprises hospital pharmacy, retail pharmacy, and online pharmacies. Hospitals recorded the highest share in 2022, but the retail pharmacy sector is expected to witness substantial growth. Retail pharmacies give patients convenient, accessible means of acquiring vital therapies and work with hospitals, healthcare providers, and specialized infusion centers to ensure prompt delivery of IVIG products. They also counsel patients on side effects, dosage instructions, and proper storage.

Route of Administration and Product Innovation

By route of administration, the market covers intravenous and subcutaneous delivery, and by end user it spans hospitals, homecare, and specialty clinics. In June 2025, Takeda announced FDA approval of GAMMAGARD LIQUID ERC, described as the only ready-to-use liquid immunoglobulin therapy containing approximately 2 µg/mL IgA in a 10% solution. Approved as a replacement treatment for primary immunodeficiency in patients aged two years and older, it can be given intravenously or subcutaneously and eliminates reconstitution.

In September 2023, Biotest received UK regulatory approval for its intravenous immunoglobulin product Yimmugo, indicated for patients with congenital and acquired immunodeficiencies.

Competitive Landscape and Challenges

The intravenous immunoglobulin market is fragmented, and players focus on partnerships, product upgrades, and collaboration. Key companies include Baxter International Inc.; BDI Pharma Inc.; Biotest AG; China Biologics Products Inc.; CSL Behring; Grifols SA; Kedrion Biopharma; LFB Biotechnologies; and Octapharma AG. North America leads regionally, while Asia Pacific is expected to grow significantly. The market is highly competitive, with many companies actively developing and commercializing IVIG therapies, resulting in a diverse range of products.

The report cites high therapy cost, potential side effects, and plasma supply constraints as challenges. As a blood product, IVIG carries a potential risk of transmitting viral infectious agents, although only a few cases of hepatitis C transmission have been reported in the distant past.

More Trending Latest Reports By Polaris Market Research:

us-jewelry-market

fiber-cement-board-market

listing-top-10-circulating-tumor-cells-companies-2025

metaverse-market

analyzing-top-10-companies-driving-growth-in-data-storage-market

polyolefins-market

us-intelligent-building-automation-technologies-market

ct-scanner-market

wind-turbine-market